<h4>Background</h4>Gemcitabine-cisplatin (GC) combined with a programmed death-ligand 1 (PD-L1) inhibitor has become an important first-line regimen for advanced intrahepatic cholangiocarcinoma (ICC). This evidence concerns the gene CD274 and intrahepatic cholangiocarcinoma.